Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after PCI in patients at high bleeding riskDepartment of Cardiology and Critical Care Medicine, Jessa ziekenhuis, Hasselt, Belgium; Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium.
Institut Cardiovasculaire Paris Sud, Ramsay Santé, Massy, France; Cardiovascular European Research Center, Massy, France.
Institut Cardiovasculaire Paris Sud, Ramsay Santé, Massy, France.
University of Galway, Galway University Hospital, Galway, Ireland.
Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
Interventional Cardiology Unit, Ospedale Luigi Sacco, Milan, Italy.
St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Interventional Cardiology Unit GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy.
Cardiology Department, The Prince Charles Hospital, Brisbane, Queensland, Australia; Faculty of Medicine University of Queensland, Brisbane, Queensland, Australia.
Department of Cardiology, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy; Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", Caserta, Italy.
Instituto Cardiovascularde Buenos Aires, Buenos Aires, Argentina.
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Cardiology, University Medical Center Maastricht, Maastricht, the Netherlands.
Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland; Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland.
Show others and affiliations
2024 (English)In: Canadian Journal of Cardiology, ISSN 0828-282X, E-ISSN 1916-7075, Vol. 40, no 9, p. 1671-1674Article in journal (Refereed) Published
Abstract [en]
In high-bleeding risk (HBR) patients, non-inferiority of 1-month dual antiplatelet therapy (APT) to treatment continuation for ≥2 additional months for the occurrence of net and major adverse clinical events after drug-eluting stent implantation was showed in the MASTER DAPT trial.1 A significant reduction in bleeding was also noted. However, whether these treatment effects of APT are consistent across geographical regions remains uncertain. In the present analyses, the effects of abbreviated or standard APT on the 1-year occurrence of net and major adverse clinical events and bleeding were consistent across geographical regions (Europe, East Asia, and others) [NCT03023020].
Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 40, no 9, p. 1671-1674
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:oru:diva-111382DOI: 10.1016/j.cjca.2024.01.032ISI: 001313457800001PubMedID: 38309468Scopus ID: 2-s2.0-85197075919OAI: oai:DiVA.org:oru-111382DiVA, id: diva2:1834590
Note
The study was sponsored by the European Cardiovascular Research Institute, a nonprofit organization, and received grant support from Terumo.
2024-02-052024-02-052024-09-26Bibliographically approved